Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Eli Lilly (LLY) has completed its acquisition of clinical-stage biopharma company AtaiBeckley, which develops rapid-acting neuroplastogens for mental health conditions, including lead investigational program BPL-003 for treatment-resistant depression.

Rhea-AI Summary

Eli Lilly (LLY) has completed its acquisition of clinical-stage biopharma company AtaiBeckley, which develops rapid-acting neuroplastogens for mental health conditions, including lead investigational program BPL-003 for treatment-resistant depression.

The deal received approval from AtaiBeckley shareholders at a special meeting held prior to closing. Lilly highlights that treatment-resistant depression persists despite multiple treatment attempts and says AtaiBeckley’s neuroplastogens may enable a new treatment paradigm focused on rapid-acting therapeutics that move away from chronic dosing. Lilly states it is committed to advancing these programs to expand options for people living with severe mental health conditions.

Positive

• Acquisition of AtaiBeckley completed, adding a clinical-stage neuroplastogen platform for mental health conditions
• Lead program BPL-003 targets treatment-resistant depression, expanding Lilly’s neuroscience pipeline focus

Negative

• None.

Market Context

The July 16 AtaiBeckley agreement was followed by a 1.08% 24-hour move; it established the transacti...

Analysis

The July 16 AtaiBeckley agreement was followed by a 1.08% 24-hour move; it established the transaction terms that preceded today’s reported closing.

Previous Acquisition Reports

1 past event · Latest: Jul 16

Same Type 1 event

1. Jul 16

   Acquisition agreement

   24h Move

   +1.1%

   Established cash consideration and contingent value rights before the reported transaction closing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

treatment-resistant depression, neuroplastogens

2 terms

treatment-resistant depression medical

"lead investigational program for treatment-resistant depression"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

neuroplastogens technical

"developing rapid-acting neuroplastogens for mental health conditions"

Neuroplastogens are drugs or molecules designed to boost the brain’s ability to reorganize and form new connections—think of them as medicines that help the brain ‘rewire’ itself after damage or during therapy. Investors watch them because successful neuroplastogens could become treatments for conditions like depression, Alzheimer’s, or brain injury, creating large markets and sharp changes in company value as trials, approvals, or setbacks occur.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.

"Treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief," said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience. "AtaiBeckley's neuroplastogens have the potential to open a new paradigm of treatment, with rapid-acting therapeutics designed to move away from chronic dosing. It's the innovation this field needs, and we are committed to advancing them for patients who need more options."

The transaction was approved by AtaiBeckley shareholders at a special meeting held prior to closing.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of Lilly, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of AtaiBeckley, Lilly's neuroscience platform and development plans, AtaiBeckley's clinical-stage pipeline of programs targeting mental health conditions, including its lead program, BPL-003, targeting treatment resistant depression, and plans for advancing AtaiBeckley's pipeline, and these statements reflect Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this press release or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release.

Refer to:	Megan Talon; megan.talon@lilly.com (Media)
	Michael Czapar; czapar_michael_c@lilly.com (Investors)

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-ataibeckley-to-advance-therapies-for-treatment-resistant-depression-and-other-mental-health-conditions-302876428.html

SOURCE Eli Lilly and Company

FAQ

What type of company is AtaiBeckley and what does it develop?

AtaiBeckley is described as a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Its work includes investigational therapies designed to act quickly and potentially reduce the need for chronic dosing.

What is BPL-003 and what condition is it intended to treat?

BPL-003 is AtaiBeckley’s lead investigational program. It is being developed for treatment-resistant depression, a form of depression that persists even after multiple treatment attempts.

Was shareholder approval required for Lilly’s acquisition of AtaiBeckley?

Yes. The transaction was approved by AtaiBeckley shareholders at a special meeting held prior to the closing of the acquisition.

How does Lilly describe the potential impact of AtaiBeckley’s neuroplastogens?

Lilly states that AtaiBeckley’s neuroplastogens have the potential to open a new paradigm of treatment in mental health by providing rapid-acting therapeutics that are designed to move away from chronic dosing, with the goal of offering more options to people with treatment-resistant depression and other conditions.